Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
146 hedge funds and large institutions have $3.6B invested in Centessa Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 48 increasing their positions, 44 reducing their positions, and 20 closing their positions.
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
60% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $6.52M
17% more funds holding
Funds holding: 125 → 146 (+21)
16% more capital invested
Capital invested by funds: $3.11B → $3.6B (+$483M)
11.11% more ownership
Funds ownership: 95.83% → 106.95% (+11%)
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
9% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$94.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$68M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$65M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
+$55.4M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$50.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
-$90.3M |
| 2 |
CC
Commodore Capital
New York
|
-$46.9M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$34.4M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$33.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26M |
CNTA Hedge Fund Activity: Q4 2025 in Review
146 of the 8,243 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q4 2025, worth a combined $3.6B — up 16% from $3.11B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new CNTA positions and 20 closed out — a net gain of 23 holders — while 48 added to existing stakes and 44 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $94.9M. The largest seller was General Atlantic, cutting an estimated $90.3M.
- 146 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q4 2025, up from 125 in Q3 2025.
- Funds reported $3.6B of Centessa Pharmaceuticals stock for Q4 2025, up 16% quarter-over-quarter.
- 43 funds opened new Centessa Pharmaceuticals positions in Q4 2025 and 20 closed out, a net change of +23 holders.
- The largest Centessa Pharmaceuticals buyer in Q4 2025 was Avoro Capital Advisors, an estimated $94.9M added.
- The largest Centessa Pharmaceuticals seller in Q4 2025 was General Atlantic, an estimated $90.3M sold.
Based on aggregated 13F filings for Q4 2025.